Cantargia’s development project exposed by leading scientific journal
On 13 September 2016 Cantargia AB (“Cantargia”) announced that an article on Cantargia’s antibodies and concept for cancer treatment had been published in the scientific journal Blood. New results in preclinical models were presented, including data on Cantargia’s CAN04 product candidate in the treatment of chronic myeloid leukemia (CML). The article has now received further attention in Blood, where it is discussed in a wider context along with data from a US research group. The two studies give a scientific support for Cantargia’s development.Cantargia is developing a cancer therapy